Accelerate Diagnostics Blood Culture Kit Demonstrates Increased Efficacy

Publication
Article
In the Lab eNewsletterPharmaceutical Technology's In the Lab eNewsletter, May 2022
Volume 17
Issue 5

Accelerate Diagnostics’ new blood culture kit demonstrated 94% or greater accuracy on positive blood cultures relative to matrix-assisted laser desorption/ionization (MALDI).

Accelerate Diagnostics, an in-vitro diagnostics company, recently announced new data on its Accelerate Arc Module and BC kit. Internal studies found that the kit demonstrated 94% or greater accuracy on positive blood cultures when compared to conventional matrix-assisted laser desorption/ionization (MALDI).

According to an April 25 company press release, one study seeded samples for 20 of the most prevalent organism species (totalling 100 isolates) that were incubated on a blood culture system (BD Bactec FX, BD). After flagging positive, the samples were then processed on the new ARC BC kit, and subsequently tested in triplicate on two MALDI systems (Bruker Biotyper, Bruker, and (Vitek MS, bioMérieux). The Arc-processed samples had an overall agreement of 100% with the Bruker Biotyper and 94% with the Vitek MS.

Another study, conducted with the Medical College of Wisconsin, processed 50 fresh positive blood cultures from the VersaTrek blood culture system on the Arc Module, which were subsequently tested in triplicate on the Bruker MALDI system. When comparing the results, it was found that the Arc enabled direct identification of microorganisms in 90% of blood cultures, with 100% agreement between the Arc and colony identification. Additionally, the Arc enabled identification in under 90 minutes, with less than five minutes of hands-on time.

“This data represents an important step in providing a workflow solution to help automate sample preparation for rapid and accurate microbial identification, saving hours of wait time and numerous manual steps to deliver results," said Shelley Campeau, co-author of the studies and director of Scientific and Clinical Affairs, Accelerate Diagnostics, in the press release.

Source: Accelerate Diagnostics

Recent Videos
Behind the Headlines episode 6
CPHI Milan 2024: Highlighting the Benefits of Integrated Services
Behind the Headlines episode 5
Buy, Sell, Hold: Cell and Gene Therapy
Buy, Sell, Hold: Cell and Gene Therapy
Buy, Sell, Hold: Cell and Gene Therapy
Related Content